Bristol-Myers Squibb Announces U.S. FDA Approval of Opdivo (nivolumab)

Monday, December 22, 2014 3:11 pm EST

Dateline:

PRINCETON, N.J.

Public Company Information:

NYSE:
BMY

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab).

Please see full Prescribing Information available at www.bms.com.

The company will provide additional details on the approval in a press release to follow.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com, or follow us on Twitter at http://twitter.com/bmsnews.

Contact:

Bristol-Myers Squibb Company
Media:
Sarah Koenig, 609-252-4145
sarah.koenig@bms.com
or
Carrie Fernandez, 609-419-5448
carrie.fernandez@bms.com
or
Christina Trank, 609-419-5497
christina.trank@bms.com
or
Investors:
John Elicker, 609-252-4611
john.elicker@bms.com
or
Ranya Dajani, 609-252-5330
ranya.dajani@bms.com

Privacy Policy
Business Wire NewsHQsm